2005
Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology
Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, Keefe DL, Blazar AS. Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Human Reproduction 2005, 21: 159-163. PMID: 16123085, DOI: 10.1093/humrep/dei270.Peer-Reviewed Original ResearchConceptsBasal FSH levelsOvarian reserveFSH levelsHCG administrationMIS levelsIVF outcomesOocyte qualityDay 3 FSH levelsMI levelsImproved oocyte qualityTime of hCGClinical pregnancy rateManagement of patientsSerum estradiol levelsHigher implantation rateEmbryo morphologyEmbryo morphology scoreNumber of oocytesEarly antral folliclesEnzyme-linked immunosorbentIVF cyclesOocyte retrievalPatient ageEstradiol levelsImplantation rate
1998
Effects of ovarian source, patient age, and menstrual cycle phase on in vitro maturation of immature human oocytes
Whitacre K, Seifer D, Friedman C, Coskun S, Kennard E, Kim M, Alak B. Effects of ovarian source, patient age, and menstrual cycle phase on in vitro maturation of immature human oocytes. Fertility And Sterility 1998, 70: 1015-1021. PMID: 9848288, DOI: 10.1016/s0015-0282(98)00339-2.Peer-Reviewed Original ResearchConceptsGerminal vesicle breakdownOvarian sourceNuclear maturationPatient ageGynecologic surgeryFollicular phaseLuteal phaseImmature human oocytesFinal meiotic maturationMenstrual cycle phaseYears of agePercentage of oocytesCycle phaseMetaphase II stageIVF programMenstrual cyclePatient criteriaMAIN OUTCOMEVitro maturationPatientsHuman oocytesOocyte maturationMII stageOocyte's abilityVesicle breakdownElevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential
Friedman C, Seifer D, Kennard E, Arbogast L, Alak B, Danforth D. Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential. Fertility And Sterility 1998, 70: 836-839. PMID: 9806563, DOI: 10.1016/s0015-0282(98)00301-x.Peer-Reviewed Original ResearchConceptsFF VEGF concentrationsAmpules of gonadotropinsVEGF concentrationsClinical pregnancyChart reviewFollicular fluid vascular endothelial growth factorFollicular fluid vascular endothelial growth factor concentrationsDay 3 FSH levelsFollicular fluid VEGF concentrationsVascular endothelial growth factor concentrationsClinical pregnancy rateEstradiol serum concentrationsPeak estradiol levelsRetrospective chart reviewUniversity teaching centerVascular endothelial growth factorNumber of oocytesYears of ageEndothelial growth factorGrowth factor concentrationsFF VEGFSingle IVFFSH levelsPatient ageEstradiol levels
1997
P-160 Effects of ovarian source, patient age, and menstrual cycle phase on in vitro maturation (IVM) of immature human oocytes
Alak B, Whitacre K, Coskun S, Kennard E, Kim M, Friedman C, Seifer D. P-160 Effects of ovarian source, patient age, and menstrual cycle phase on in vitro maturation (IVM) of immature human oocytes. Fertility And Sterility 1997, 68: s169-s170. DOI: 10.1016/s0015-0282(97)90975-4.Peer-Reviewed Original Research
1994
Dehydroepiandrosterone sulfate and anovulation increase serum inhibin and affect follicular function during administration of gonadotropins
Haning RV, Hua JJ, Hackett RJ, Wheeler CA, Frishman GN, Seifer DB, Dahl CA, Burger HG. Dehydroepiandrosterone sulfate and anovulation increase serum inhibin and affect follicular function during administration of gonadotropins. The Journal Of Clinical Endocrinology & Metabolism 1994, 78: 145-149. PMID: 8288697, DOI: 10.1210/jcem.78.1.8288697.Peer-Reviewed Original ResearchConceptsNumber of oocytesAnovulatory subjectsSerum inhibinAnovulatory ovariesSerum concentrationsNormal subjectsSerum DS concentrationSerum inhibin concentrationsAdministration of gonadotropinSecretion of inhibinResidual serum samplesDuration of treatmentAnovulatory patientsGonadotropin therapyInhibin concentrationsInhibin secretionPatient ageFertilization cyclesGonadotropin treatmentLH dosesFollicular functionHCG treatmentInhibinAverage durationSerum samples